ScholarIQanswers from OpenAlex & ORCID
Dong‐Wan Kim
ResearcherPublications, citations & collaboration network
Dong‐Wan Kim is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Dong‐Wan Kim have?
ScholarIQindexed works
Dong‐Wan Kim has 725 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dong‐Wan Kim have?
ScholarIQcitation count
Dong‐Wan Kim has 33,791 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Dong‐Wan Kim?
ScholarIQh-index
Dong‐Wan Kim has an h-index of 73 in OpenAlex.
What is the i10-index of Dong‐Wan Kim?
ScholarIQi10-index
Dong‐Wan Kim has an i10-index of 272 in OpenAlex.
What is the ORCID of Dong‐Wan Kim?
ScholarIQorcid
The ORCID for Dong‐Wan Kim is on the source record.
What is the OpenAlex record for Dong‐Wan Kim?
ScholarIQopenalex
The OpenAlex for Dong‐Wan Kim is on the source record.
What are the most-cited papers on Dong‐Wan Kim?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok
Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes
Ki Tae Nam, Dong‐Wan Kim, Pil J. Yoo, C.‐Y. Chiang, Nonglak Meethong, Paula T. Hammond, Yet‐Ming Chiang, Angela M. Belcher
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazières, Dong‐Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna Maria Calella, Gerson Peltz, Benjamin Solomon